Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593

Synapse

Volumn 61, Issue 9, 2007, Pages 771-777

  Fuentealba, José Antonio ^a   Gysling, Katia ^a   Andrés, María Estela ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Amphetamine; Dopamine; Kappa opioid receptor; Microdialysis; Nucleus accumbens

Indexed keywords

AMPHETAMINE; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG DOSE INCREASE; LOCOMOTION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZENEACETAMIDES; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; MALE; MICRODIALYSIS; MOTOR ACTIVITY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 34547196386     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20424     Document Type: Article

References (29)

1. Acri JB, Thompson AC, Shippenberg T. 2001. Modulation of pre-and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39:343-350.
2. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS. 2005. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25:5029-5037.
3. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
4. Donzanti BA, Althaus JS, Payson MM, Von Voigtlander PF. 1992. Kappa agonist-induced reduction in dopamine release: Site of action and tolerance. Res Commun Chem Pathol Pharmacol 78:193-210.
5. Fuentealba JA, Forray MI, Gysling K. 2000. Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of the stria terminalis. J Neurochem 75:741-748.
6. Fuentealba JA, Gysling K, Magendzo K, Andres ME. 2006. Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens. J Neurosci Res 84:450-459.
7. Gray AM, Rawls SM, Shippenberg TS, McGinty JF. 1999. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73:1066-1074.
8. Heidbreder CA, Shippenberg TS. 1994. U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine. Neuroreport 5:1797-1800.
9. Heidbreder CA, Schenk S, Partridge B, Shippenberg TS. 1998. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 30:255-262.
10. Izenwasser S, Acri JB, Kunko PM, Shippenberg T. 1998. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse 30:275-283.
11. Kuzmin A, Sandin J, Terenius L, Ogren SO. 2000. Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice. J Pharmacol Exp Ther 295:1031-1042.
12. 3H]U-69593 a highly selective ligand for the kappa-opioid receptor. Eur J Pharmacol 109:281-284.
13. Maisonneuve IM, Archer S, Glick SD. 1994. U-50488, a kappa opioid receptor agonits, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60.
14. Mello NK, Negus S. 2000. Interaction between kappa opioid agonist and cocaine. Preclinical studies. Ann N Y Acad Sci 909:105-132.
15. Meshul CK, McGinty JF. 2000. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96:91-99.
16. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. Sydney: Academic Press.
17. Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H. 2006. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: Pre- and postsynaptic mechanisms. Neuropsychopharmacology 31:1967-1981.
18. Pierce RC, Kalivas PW. 1997. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216.
19. Prisinzano TE, Tidgewell K, Harding WW. 2005. Kappa opioids as potential treatments for stimulant dependence. AAPS J 7:E592-E599.
20. Roitman MF, Wheeler RA, Carelli RM. 2005. Nucleus accumbens neurons are innately tuned for rewarding and aversive taste stimuli, encode their predictors, and are linked to motor output. Neuron 45:587-597.
21. Ronken E, Mulder AH Schoffelmeer AN. 1994. Chronic activation of mu-and kappa-opioid receptors in cultured catecholaminergic neurons from rat brain causes neuronal supersensivity without receptor desensitization. J Pharmacol Exp Ther 268:595-599.
22. Schenk S, Partridge B. 2001. Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine self-administration behavior. Pharmacol Biochem Behav 68:629-634.
23. Schenk S, Partridge B, Shippenberg TS. 1999. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144:339-346.
24. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. 1987. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401:322-330.
25. Spanagel R, Herz A, Shippenberg TS. 1990. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J Neurochem 55:1734-1740.
26. Spanagel R, Herz A, Shippenberg TS. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050.
27. Svingos AL, Chavkin C, Colago EE, Pickel VM. 2001. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42:185-192.
28. Thompson AC, Zapata A, Justice JB Jr, Vaughan RA, Sharpe LG, Shippenberg TS. 2000. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20:9333-9340.
29. Vecchiola A, Collyer P, Figueroa R, Labarca R, Bustos G, Magendzo K. 1999. Differential regulation of mu-opioid receptor mRNA in the nucleus accumbens shell and core accompanying amphetamine behavioral sensitization. Brain Res Mol Brain Res 69:1-9.